In an effort to combine the underlying gene expressions in a model for predicting gemcitabine sensitivity, it was demonstrated that a ratio of mRNA expression of [(hENT1 × dCK)/(RRM1 × RRM2)] decreased progressively with the development of acquired resistance to gemcitabine in pancreatic cancer cells [70]. Here, RRM1 is linked to pancreatic neoplasm.